ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018
Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry.Cancer biotherapy & radiopharmaceuticals · 2023Article
- Clinical Advances and Perspectives in Targeted Radionuclide Therapy.Pharmaceutics · 2023Review
- Development of a Compartmental Pharmacokinetic Model for Molecular Radiotherapy withPharmaceutics · 2021Article
- Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.Science translational medicine · 2021Article
- Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.Theranostics · 2021Article
- Radiopharmaceutical therapy in cancer: clinical advances and challenges.Nature reviews. Drug discovery · 2020Review
- Theragnostic Aspects and Radioimmunotherapy in Pediatric Tumors.International journal of molecular sciences · 2020Review
- Radiopharmaceuticals for Treatment of Osteosarcoma.Advances in experimental medicine and biology · 2020Review
- Advanced Cancer Imaging Applied in the Comparative Setting.Frontiers in oncology · 2020Article
- Preclinical Pharmacokinetics and Dosimetry Studies ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Enhanced Radiosensitivity in Solid Tumors using a Tumor-selective Alkyl Phospholipid Ether Analog.Molecular cancer therapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
External-beam radiotherapy plays a critical role in the treatment of most pediatric solid tumors. Particularly in children, achieving an optimal therapeutic index to avoid damage to normal tissue is extremely important. Consequently, in metastatic disease, the utility of external-beam radiotherapy is limited. Molecular radiotherapy with tumor-targeted radionuclides may overcome some of these challenges, but to date there exists no single cancer-selective agent capable of treating various pediatric malignancies independently of their histopathologic origin. We tested the therapeutic potential of the clinical-grade alkyl-phospholipid ether analog CLR1404, 18-(
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.